98%
921
2 minutes
20
The mucosal immune system represents a critical defense mechanism, safeguarding the body from an array of external pathogens. As the body's first line of immune protection, it plays an essential role in initiating both innate and adaptive immune responses. Through intricate networks of immune cells and complex molecular pathways, mucosal immunity orchestrates a robust defense not only at the local level but also activates systemic immune responses to ensure comprehensive protection. Consequently, the mucosal immune system has garnered immense interest in the field of vaccine development, given its potential to foster durable and effective immunization. Despite the profound promise of mucosal immunity, the development of mucosal vaccines faces significant challenges, particularly with existing technological platforms that primarily rely on live attenuated or inactivated vaccines. However, emerging innovative platforms, including subunit vaccines, viral vector vaccines, and the groundbreaking application of mRNA vaccines, are offering new perspectives, vastly improving the scope and efficacy of mucosal immunization. As mucosal immunity research continues to evolve, rapid advancements in biotechnology and immunology provide promising strategies to enhance immune responses and overcome inherent limitations. This review delves into the latest progress in oral, nasal, and other forms of mucosal vaccines, analyzing the intricate relationship between mucosal immune characteristics and vaccine design. Emphasis is placed on the pivotal role of advanced adjuvants and delivery systems in maximizing vaccine efficacy. This review addresses current challenges, highlights future research opportunities, and aims to provide a comprehensive framework for advancing the field of mucosal immunity and vaccine development.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12364801 | PMC |
http://dx.doi.org/10.1186/s43556-025-00301-7 | DOI Listing |
Microb Pathog
September 2025
School of Life Science, Liaoning University, Chongshanzhong-Lu No. 66, Shenyang, 110036, China. Electronic address:
Mycoplasma gallisepticum (MG) is one of the main pathogens causing chronic respiratory diseases in chickens, which seriously affects the sustainable and healthy development of the poultry industry and leading to heavy economic losses. Therefore, we developed a safe, efficient, convenient, and low-cost MG oral vaccine. The vaccine is based on a recombinant yeast surface display system to compensate for the shortcomings of existing vaccines.
View Article and Find Full Text PDFCell
September 2025
Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA. Electronic address:
Adaptation of intestinal helminths to vertebrates involved the evolution of strategies to attenuate host tissue damage to support parasite reproduction and dissemination of offspring to the environment. Helminths initiate the IL-25-mediated tuft cell-type 2 innate lymphoid cell (ILC2) circuit that enhances barrier protection of the host, although viable parasites can target and limit this pathway. We used IL-25 alone to create small intestinal adaptation, marked by anatomic and immunologic changes that persisted months after induction.
View Article and Find Full Text PDFPoult Sci
August 2025
Optima Life Sciences Private Limited, Pune Maharashtra, 411009, India.
Antibiotic growth promoters (AGPs) are increasingly subject to global regulatory restrictions and consumer pressure, driving the poultry industry toward antibiotic-free production systems. This shift has accelerated the search for effective alternatives, including innovative microbial additives, organic acids, phytogenics, and other bioactive compounds capable of supporting digestive function and enhancing immune competence in poultry. The present study reported the isolation and characterization of a novel Bacillus velezensis strain, BV-OLS1101, possessing robust probiotic attributes and a distinctive capacity to produce a serine protease subtilisin.
View Article and Find Full Text PDFAntiviral Res
September 2025
Department of Immunology and Pathogen Biology, Key Laboratory of Pathogen and Host-Interactions, Ministry of Education, School of Medicine, Tongji University, Shanghai 200331, China. Electronic address:
DMBT1 is a large scavenger receptor cysteine rich (SRCR) B protein that has been reported as a tumor suppressor gene and a co-receptor for HIV-1 infection. Here we found DMBT1 is a major mucosal protein bound to SARS-CoV-2. Overexpression of DMBT1 in 293T cells may enhanced infection by SARS-CoV-2 in ACE2 dependent manner.
View Article and Find Full Text PDFFish Shellfish Immunol
September 2025
Key Laboratory of Aquaculture Nutrition and Feed, Ministry of Agriculture, The Key Laboratory of Mariculture, Ministry of Education, Ocean University of China, Qingdao, 266003, China; Qingdao National Laboratory for Marine Science and Technology, Qingdao, 266237, China. Electronic address: yanjiaozh
This study investigated the protective effects of dietary niacin on the intestinal health of juvenile turbot fed a high-lipid diet (HLD). Two isonitrogenous and isolipidic diets were formulated, including a HLD without niacin addition (HL0) and a HLD supplemented with 80 mg/kg niacin (HL80). Turbot (approximately 13.
View Article and Find Full Text PDF